Company intelligence / Profile preview
Saisei Mirai
Osaka, Osaka, Japansaisei-mirai.or.jp ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Saisei Mirai has developed proprietary GcMAF-based immunotherapies, demonstrating a favorable safety profile and clinical application in hundreds of patients, with published evidence for immune modulation and experimental results showing telomere extension and increased Klotho expression in animal models[4][6].
- Therapeutic areas
- PsychiatryImmunologyNeurologyInfectious DiseasesOtherOncology
- Modalities
- BiologicGene therapySmall moleculeCell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaborations with several Japanese and international universities and medical institutions, including University of Tokushima[4][1]
Beyond the preview
Go deeper on Saisei Mirai.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saisei Mirai.